No Data
Tonghua Dongbao Pharmaceutical (600867.SH): The company's first gout product based on Etoricoxib tablets was approved this January.
On February 28, according to Gelonghui, Tonghua Dongbao Pharmaceutical (600867.SH) stated on the investor interaction platform that the company's first gout product, relying on the drug Paracetamol tablets, was approved in January this year. Currently, two innovative drugs for gout under research are both in Phase II clinical trials. Among them, the Phase IIa clinical trial of the URAT1 inhibitor has reached the primary endpoint, while the Phase IIa clinical trial of the XO/URAT1 dual-target inhibitor with First-in-class potential has completed database locking.
Tonghua Dongbao Pharmaceutical Unit Completes Phase Ib Clinical Trial for Diabetes Drug
Tonghua Dongbao Pharmaceutical (600867.SH): Actively exploring the application of AI technology in drug development and related Operation.
On February 27, Gelonghui reported that Tonghua Dongbao Pharmaceutical (600867.SH) stated on the investor interaction platform that the company continuously focuses on the development of AI technology and its applications in related fields, actively exploring the use of AI technology in drug research and development as well as related operations to continuously improve research and development and operation efficiency.
Tonghua Dongbao: Tonghua Dongbao 2024 Annual Results Forecast Correction Announcement
Tonghua Dongbao 2024 Annual Results Forecast Correction Notice
The final judgment resulted in a compensation exceeding 60 million yuan, Tonghua Dongbao Pharmaceutical revised its performance forecast | Interpretations
① The final judgment requires compensation to Gan & Lee Pharmaceuticals exceeding 60 million yuan, and Tonghua Dongbao Pharmaceutical adjusts its performance for 2024; ② The company's controlling shareholder Dongbao Group has pledged shares amounting to nearly 30% of the company's total equity.
Insufficient Growth At Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Hampers Share Price
